PER 34.1% 8.9¢ percheron therapeutics limited

For General Information, page-784

  1. 3,222 Posts.
    lightbulb Created with Sketch. 574
    good he's getting out there. Would love a quicker spotlight on what investors want to hear; best phase two trial results seen thus far, entering pahse 2b/3 in EU, possible cross over to USA market, proven action in other indications, Covid analysis currently happening. Combo studies ongoing. I guess if you're new to us Marks introduction is the foundation.
 
watchlist Created with Sketch. Add PER (ASX) to my watchlist
arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.